Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | April 26, 2013 | April 30, 2013 |
| Walgreens Boots Alliance, Inc.WBA · Entity 16467 | Director | November 01, 2018 | November 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 26, 2013 · Filed April 30, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,202 |
Reported balance
After 2013-04-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2013-04-26 · Grant · Acquired 1,845 · Balance 18,202 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2: These shares include 102 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
F2: These shares include 102 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Walgreens Boots Alliance, Inc.
Report date November 01, 2018 · Filed November 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,954 |
Reported balance
After 2018-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-01 · Grant · Acquired 2,503.129 · Balance 8,954 F1: The phantom stock is issued as non-employee director compensation under the amended and restated Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (including the applicable election forms thereunder, the "Plan"), and each unit of phantom stock is the economic equivalent of one share of the company's common stock. F2: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F3: Includes phantom stock units issued in lieu of dividends (through September 30, 2018) on outstanding phantom stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock is issued as non-employee director compensation under the amended and restated Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (including the applicable election forms thereunder, the "Plan"), and each unit of phantom stock is the economic equivalent of one share of the company's common stock.
F2: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan.
F3: Includes phantom stock units issued in lieu of dividends (through September 30, 2018) on outstanding phantom stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
1 source rowRow 1 · 2025-10-07 · Other · Disposed 68,796 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Schaeffer Holdings LLC | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-10-07 · Other · Disposed 43,104 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,
F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001193125-25-233539 · ownership.xml · derivative · entry 5 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001193125-25-233539 · ownership.xml · derivative · entry 4 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001193125-25-233539 · ownership.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | OtherCommon Stock | 43,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-233539 · ownership.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Schaeffer Holdings LLC Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2 · price: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | OtherCommon Stock | 68,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-233539 · ownership.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2 · price: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:42 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000950170-25-082425 · ownership.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000950170-24-101432 · ownership.xml · derivative · entry 4 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,223 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0000950170-24-101432 · ownership.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,223 shares Expires 2024-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionCommon Stock | 6,124 | $3.37 | $20,637.88 |
DisclosureSEC source: 0000950170-24-101432 · ownership.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionCommon Stock | 5,223 | $1.66 | $8,670.18 |
DisclosureSEC source: 0000950170-24-101432 · ownership.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:00 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-24-073127 · ownership.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 17,300 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-23-014855 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000899243-22-022573 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 14, 2023, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:50 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000899243-21-022980 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2031-06-08 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0000899243-20-016162 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2030-06-09 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:21 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-017644 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 17:00 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantPhantom Stock Units · Derivative | 2,503.129 | $79.90 | $200,000.01 |
DisclosureSEC source: 0001618921-18-000082 · edgar.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,954 Underlying: Common Stock · 2,503.129 shares Expires not disclosed F1 · derivative.exercise_price: The phantom stock is issued as non-employee director compensation under the amended and restated Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan (including the applicable election forms thereunder, the "Plan"), and each unit of phantom stock is the economic equivalent of one share of the company's common stock. F2 · derivative.exercise_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F2 · derivative.expiration_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F3 · balance_after: Includes phantom stock units issued in lieu of dividends (through September 30, 2018) on outstanding phantom stock units. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 18:39 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0000899243-18-017633 · doc4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2028-06-19 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 19, 2019, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:18 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,631 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0000899243-17-029322 · doc4.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,223 Underlying: Common Stock · 22,631 shares Expires 2024-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares vested on September 17, 2015, and an additional 1/48th vests on the last day of each one month period thereafter. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:18 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Exercise / conversionCommon Stock | 22,631 | $1.66 | $37,567.46 |
DisclosureSEC source: 0000899243-17-029322 · doc4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:27 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 309,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027200 · doc4.xml · derivative · entry 4 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Schaeffer Holdings LLC Disclosed balance after: 0 Underlying: Common Stock · 43,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F2 · ownership.nature: The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:27 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027200 · doc4.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F3 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:27 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 43,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027200 · doc4.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Schaeffer Holdings LLC Disclosed balance after: 43,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by the Reporting Person and Schaeffer Holdings LLC upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:27 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 34,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027200 · doc4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by the Reporting Person and Schaeffer Holdings LLC upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 17:26 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantPhantom Stock Units · Derivative | 2,984.629 | $67.01 | $199,999.99 |
DisclosureSEC source: 0001618921-17-000096 · edgar.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,299.7 Underlying: Common Stock · 2,984.629 shares Expires not disclosed F1 · derivative.exercise_price: The phantom stock is issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan, as amended (including the applicable election forms thereunder, the "Plan"), and each unit of phantom stock is the economic equivalent of one share of the company's common stock. F2 · derivative.exercise_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F2 · derivative.expiration_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F3 · balance_after: Includes phantom stock units issued in lieu of dividends (through September 30, 2017) on outstanding phantom stock units. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 17:15 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantPhantom Stock Units · Derivative | 2,304.147 | $82.46 | $189,999.96 |
DisclosureSEC source: 0001618921-16-000088 · edgar.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255.7 Underlying: Common Stock · 2,304.147 shares Expires not disclosed F1 · derivative.exercise_price: The phantom stock is issued as non-employee director compensation under the Walgreens Boots Alliance, Inc. 2013 Omnibus Incentive Plan, as amended (including the applicable election forms thereunder, the "Plan"), and each unit of phantom stock is the economic equivalent of one share of the company's common stock. F2 · derivative.exercise_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F2 · derivative.expiration_date: To be settled following termination of service as a director in accordance with the terms and conditions of the Plan. F3 · balance_after: Includes phantom stock units issued in lieu of dividends (through September 30, 2016) on outstanding phantom stock units. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 22:08 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014811 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,202 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 102 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · derivative · entry 7 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · derivative · entry 6 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $62.55 | $0.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · derivative · entry 5 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2014-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $87.92 | $1,318,830.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 4 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,329 F1 · price: The price reported is an average price. The prices ranged from $87.90 to $87.97 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include 74 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $50.44 | $252,200.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $42.13 | $210,650.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2012 Filed Dec 11, 2012 00:09 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $62.55 | $312,750.00 |
DisclosureSEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2012 Filed Aug 31, 2012 22:00 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $74.89 | $0.00 |
DisclosureSEC source: 0001127602-12-025539 · form4.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2013-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2012 Filed Aug 31, 2012 22:00 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 5,000 | $83.25 | $416,253.50 |
DisclosureSEC source: 0001127602-12-025539 · form4.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,316 F1 · price: The price reported is an average price. The prices ranged from $83.23 to $83.26 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include 61 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 30, 2012 Filed Aug 31, 2012 22:00 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $74.89 | $374,450.00 |
DisclosureSEC source: 0001127602-12-025539 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2012 Filed May 2, 2012 00:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $71.64 Strike: $71.64 | $358,200.00 |
DisclosureSEC source: 0001127602-12-015235 · form4.xml · derivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-04-27 Read SEC document |
| April 27, 2012 Filed May 2, 2012 00:03 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-015235 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 F1 · shares: The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the "Director Program") and vested immediately because the director has three years or more of prior continuous service as a director. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 45 Dividend Equivalents ("DEs") granted pursuant to the Director Program. The acquisition of DEs had previously been reported in Table II of the director's Form 4 filings prior to the Company implementing a qualifying dividend reinvestment plan in 2012. DEs are credited on the director's unvested, and vested but deferred, RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 16, 2012 Filed Feb 17, 2012 00:20 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001127602-12-006488 · form4.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2012-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2012 Filed Feb 17, 2012 00:20 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,316 | $67.90 | $293,056.40 |
DisclosureSEC source: 0001127602-12-006488 · form4.xml · nonDerivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,860 Read SEC document |
| February 16, 2012 Filed Feb 17, 2012 00:20 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $58.61 | $293,050.00 |
DisclosureSEC source: 0001127602-12-006488 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2011 Filed Dec 13, 2011 00:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 14.3491 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-031955 · form4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29.4249 Underlying: Common Stock · 14.3491 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 08, 2011 Filed Sep 12, 2011 21:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 15.0758 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-025067 · form4.xml · derivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15.0758 Underlying: Common Stock · 15.0758 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $54.69 Strike: $54.69 | $273,450.00 |
DisclosureSEC source: 0001127602-11-013866 · form4.xml · derivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-04-25 Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013866 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,176 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $58.43 Strike: $58.43 | $292,150.00 |
DisclosureSEC source: 0001127602-10-012356 · form4.xml · derivative · entry 2 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-26 Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-012356 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-09-010059 · form4.xml · derivative · entry 3 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-04-28 Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-09-010059 · form4.xml · nonDerivative · entry 1 SCHAEFFER LEONARD D · CIK 0001016369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous services as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.